Halozyme Therapeutics, Inc. Earnings

Halozyme Therapeutics, Inc.’s revenue jumped 29.55% since last year same period to $298.01Mn in the Q4 2024. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 2.73% jump in its revenue since last 3-months.

Halozyme Therapeutics, Inc.’s net profit jumped 60.46% since last year same period to $137.01Mn in the Q4 2024. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 0% jump in its net profits since last 3-months.

Halozyme Therapeutics, Inc.’s net profit margin jumped 23.86% since last year same period to 45.98% in the Q4 2024. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -2.66% fall in its net profit margins since last 3-months.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.97 - a -16.12% fall from last quarter’s estimates.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 0.97.

Halozyme Therapeutics, Inc.’s earning per share (EPS) jumped 53.66% since last year same period to 1.26 in the Q4 2024. This indicates that the Halozyme Therapeutics, Inc. has generated 53.66% annual rate of jump in its earning per share (EPS) in the last 4 quarters.